Back to search

Article

Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies

2024-12-20

Abstract excerpt

<h4>ABSTRACT</h4> Receptor tyrosine kinase ERBB4 (HER4) is frequently mutated in human cancer, and ERBB4 mutations have been identified in patients relapsing on targeted therapy. Here, we addressed the functional consequences of recurrent cancer-associated ERBB4 mutations that are located at regions important for dimer interactions and/or are paralogous to known oncogenic hotspot mutations in other ERBB genes....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f7fcfa9d-11ac-55ac-95eb-07123a6d9257
DOI
10.1101/2024.12.19.626686
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapiesDOI 10.1101/2024.12.19.626686
Select a neighboring publication to make it the new centre.